US FDA extends review of Lantheus' diagnostic imaging kit by three months
17/03/2026 20:16
March 17 (Reuters) - Lantheus Holdings LNTH.O said on Tuesday that the U.S. Food and Drug Administration has extended its review of the company's diagnostic imaging kit by three months. The agency will now give its decision on the imaging kit's approval by June 29. (Reporting by Kamal Choudhury in Bengaluru; Editing by Shailesh Kuber) ((Kamal.Choudhury@thomsonreuters.com;))
Recent news on Lantheus Holdings
See all newsBrief: Lantheus Receives Complete Response Letter From FDA For Lnth-2501 (Ga 68 Edotreotide)
US FDA declines Lantheus’ tumor imaging kit over third-party manufacturing issues (updated)
US FDA declines to approve Lantheus’ tumor imaging kit
$7 billion could be a 'light' price tag for Lantheus, Truist analysts say
Lantheus falls after report it is considering potential $7 billion sale